Register for our free email digests:
Latest From Indivior PLC
Commissioner Gottlieb says FDA is looking to work with provider groups to set dosage based on indication; Patrick Kennedy is calling on CMS to provide reimbursement for opioid addiction treatment.
Shares in Indivior slid nearly 40% on news of a US court ruling which raises chances its key opioid addiction treatment may face generic competition sooner than expected.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- Reckitt Benckiser Pharmaceuticals Inc.
- Western Europe
- Company Type
- Parent & Subsidiaries
- Indivior PLC
- Senior Management
Shaun Thaxter, CEO
Cary Claiborne, CFO
Tim Baxter, MD, CMO
Tony Goodman, Chief Bus. Dev. Officer
Christian Heidbreder, PhD, CSO
Richard Simkin, Chief Commercial Officer
- Contact Info
Phone: (0)1753 217800
215 Bath Rd.
Slough, SL1 4AA
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.